🔍

CAMLINFINE - Camlin Fine

📊 NSE: CAMLINFINE 🏢 Chemicals 📅 Last Updated: 12/13/2025 20:39

📢 Recent Corporate Announcements

Camlin Fine Sciences: Infinity Direct Capital Declares No New Share Encumbrances in FY26

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Apr 2026, 12:50 PM

Infinity Direct Capital, a promoter group entity of Camlin Fine Sciences, has filed its annual declaration under Regulation 31(4) of SEBI Takeover Regulations. The disclosure confirms that the entity has not created any new encumbrances or pledges on its shareholding during the financial year ended March 31, 2026, beyond what was already disclosed. This is a standard annual compliance procedure intended to provide transparency regarding promoter share pledging. Such filings are routine for listed Indian companies at the start of a new financial year.

Declaration submitted under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Covers the entire financial year period ending March 31, 2026.
Confirms no additional direct or indirect encumbrances were made on company shares during the year.
The disclosure was submitted to both NSE and BSE as well as the company's Audit Committee.

💡 This is a routine regulatory filing with no immediate impact on stock valuation. Investors should simply note the continued transparency regarding promoter share pledges.

Camlin Fine Sciences: Infinity Portfolio Holdings Declares No New Share Encumbrances in FY26

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Apr 2026, 12:29 PM

Infinity Portfolio Holdings, a member of the promoter group for Camlin Fine Sciences, has submitted its annual declaration under SEBI Takeover Regulations for the financial year ended March 31, 2026. The entity confirmed that no new encumbrances or pledges were created on its shareholding, directly or indirectly, during the period, other than those already disclosed. This is a standard regulatory requirement aimed at maintaining transparency regarding promoter share pledging. Such filings are routine and indicate compliance with Indian securities laws.

Declaration submitted under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Covers the full financial year period ending March 31, 2026.
Infinity Portfolio Holdings confirms no additional share encumbrances were made beyond previous disclosures.
The disclosure was filed with both NSE and BSE as well as the company's Audit Committee.

💡 No action is required as this is a routine annual compliance filing; investors should simply note the stability in promoter pledging status.

Camlin Fine Sciences Promoter Declares No New Share Encumbrances for FY 2025-26

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 28 Apr 2026, 05:41 PM

Infinity Direct Holdings, a promoter entity of Camlin Fine Sciences Limited, has submitted its annual declaration under SEBI Takeover Regulations for the financial year ended March 31, 2026. The promoter confirmed that no new encumbrances or pledges were created on their shareholding during the year, other than those already disclosed. This is a mandatory annual compliance filing aimed at maintaining transparency regarding promoter shareholding. For investors, this confirms that the promoter's leverage against company shares has not increased during the period.

Promoter entity Infinity Direct Holdings filed the declaration under Regulation 31(4) of SEBI Takeover Regulations.
The disclosure confirms no additional encumbrances were made during the financial year ended March 31, 2026.
The declaration was submitted to both the National Stock Exchange (NSE) and BSE Limited.
The filing ensures compliance with transparency norms regarding promoter share pledging activities.

💡 This is a routine regulatory filing and requires no immediate action. Investors should monitor the quarterly shareholding pattern to track any changes in the total percentage of promoter pledges.

Camlin Fine Sciences Promoter Declares No New Share Encumbrances for FY 2025-26

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 28 Apr 2026, 05:40 PM

Infinity Direct Holdings, a promoter of Camlin Fine Sciences Limited, has submitted a formal declaration under Regulation 31(4) of the SEBI Takeover Regulations. The promoter confirmed that no new encumbrances or pledges were created on their shareholding during the financial year ended March 31, 2026, other than those already disclosed. This is a standard annual compliance filing intended to provide transparency regarding promoter share pledging activities. The disclosure ensures that the promoter's leverage against company shares has not increased unexpectedly during the year.

Promoter Infinity Direct Holdings confirms zero additional share encumbrances for FY 2025-26.
Declaration filed pursuant to Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
The disclosure was submitted to both NSE and BSE stock exchanges on April 02, 2026.
Confirmation provided to the Audit Committee of Camlin Fine Sciences Ltd regarding direct and indirect holdings.

💡 This is a routine regulatory filing with no impact on company fundamentals. Investors should monitor the quarterly shareholding pattern for any changes in the total percentage of pledged promoter shares.

Camlin Fine Sciences Promoter Anfima NV Declares No New Share Encumbrances in FY24

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 21 Apr 2026, 12:40 PM

Promoter entity Anfima NV has submitted a formal declaration under SEBI Takeover Regulations for the financial year ended March 31, 2024. The filing confirms that no new encumbrances or pledges were created on the shares held by the promoter group, directly or indirectly, beyond what was already disclosed. This is a routine compliance requirement aimed at ensuring transparency regarding promoter shareholding stability. Such disclosures are mandatory for all listed companies at the end of each financial year to inform the exchanges and the audit committee.

Declaration made under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Promoter entity Anfima NV confirms no additional encumbrances were made during the financial year.
The disclosure covers the period ending March 31, 2024, ensuring transparency in promoter holdings.
Submission made to both NSE and BSE as per regulatory requirements.

💡 No action is required as this is a standard annual compliance filing. It confirms that the promoter's pledged position remains unchanged from previous disclosures.

Camlin Fine Sciences Receives ₹5.47 Crore Income Tax Demand Notice

🔵 WATCH ⭐ 4/10

REGULATORY 📅 10 Apr 2026, 04:52 PM

Camlin Fine Sciences Limited has received a notice of demand for ₹5.47 crore from the Income Tax Department for the Assessment Year 2023-24. The demand is primarily due to Arm’s Length Price (ALP) adjustments regarding international and domestic transactions with its Associated Enterprises. The company has been directed to deposit the amount within 30 days but has stated its intention to file an appeal against the order. Management currently expects no significant impact on the company's operations or financial activities.

Tax demand of ₹5,46,98,560 issued under section 156 of the Income-Tax Act, 1961.
The order pertains to Assessment Year 2023-24 following an assessment under section 143(3).
Dispute relates to transfer pricing adjustments (Arm’s Length Price) for transactions with Associated Enterprises.
The company is in the process of filing an appeal to contest the demand.

💡 Investors should monitor the progress of the appeal, as transfer pricing disputes are common in global operations but can lead to protracted legal processes. The current demand amount is not large enough to pose a systemic risk to the company's liquidity.

Camlin Fine Sciences Files Quarterly SEBI Compliance Certificate for Q4 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Apr 2026, 11:54 AM

Camlin Fine Sciences Limited has submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The certificate, issued by the Registrar and Share Transfer Agent MUFG Intime India Private Limited, confirms that share certificates received for dematerialization were processed within prescribed timelines. It also verifies that the securities have been listed on the stock exchanges where earlier shares were listed. This is a standard administrative filing required by all listed Indian companies.

Compliance certificate submitted for the quarter ended March 31, 2026.
Issued by Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
Confirms dematerialization requests were processed and certificates cancelled as per SEBI norms.
Ensures all dematerialized shares are correctly listed on BSE and NSE.

💡 No action is required from investors as this is a routine regulatory compliance filing. Investors should monitor the company's upcoming quarterly financial results for material performance updates.

Camlin Fine Sciences Receives GST Demand and Penalty Totaling Rs 1.93 Crore

🔴 NEGATIVE ⭐ 4/10

REGULATORY 📅 31 Mar 2026, 04:52 PM

Camlin Fine Sciences Limited has received an order from the CGST & Central Excise department for a tax demand of Rs. 96.66 lakh and an equivalent penalty of Rs. 96.66 lakh. The order relates to the non-payment of tax under the Reverse Charge Mechanism (RCM) on foreign currency expenses reimbursed to subsidiaries between FY 2019-20 and FY 2022-23. Including interest, the total financial implication is approximately Rs. 1.93 crore. The company has stated that this order has no material impact on its operations and it is currently in the process of filing an appeal.

Tax demand of Rs. 96,65,820 (IGST) raised under Section 74(9) of the CGST Act.
Penalty of Rs. 96,65,820 imposed for alleged short/non-payment of tax.
Dispute pertains to tax on foreign currency reimbursements to subsidiaries under RCM for FY 2019-20 to 2022-23.
Company intends to file an appeal against the order and claims no material operational impact.

💡 Investors should monitor the progress of the appeal as it involves tax interpretations on subsidiary transactions. While the amount is not critically large for the company's scale, it represents a minor regulatory headwind.

Camlin Fine Sciences to Close Trading Window from April 1 for FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Mar 2026, 05:37 PM

Camlin Fine Sciences Limited has announced the closure of its trading window effective from April 1, 2026. This action is taken in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the release of audited standalone and consolidated financial results for the quarter and year ending March 31, 2026. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are officially declared. The specific date for the board meeting to approve these results will be communicated at a later date.

Trading window closure starts from April 1, 2026, for the FY26 year-end results.
The closure applies to all Insiders, Designated Persons, and their immediate relatives.
Window will reopen 48 hours after the declaration of audited standalone and consolidated results.
The board meeting date for financial result approval is yet to be announced.

💡 This is a routine regulatory announcement with no impact on company fundamentals. Investors should monitor for the upcoming board meeting date to assess the company's full-year financial performance.

Camlin Fine Sciences Subsidiary CFS Europe Enters Judicial Liquidation in Italy

🔴 NEGATIVE ⭐ 7/10

LEGAL 📅 18 Mar 2026, 05:36 PM

Camlin Fine Sciences has announced that its wholly-owned Italian subsidiary, CFS Europe S.p.A., has entered judicial liquidation following an order from the Ordinary Court of Ravenna, Italy. The subsidiary contributed approximately 4.72% to the company's consolidated turnover and 9.73% to its net worth as of March 31, 2025. The proceedings are being conducted under the Italian Code of Corporate Crisis and Insolvency with court-appointed liquidators now managing the process. Any potential recovery for the parent company will depend on the remaining proceeds after the liquidation of liabilities.

CFS Europe S.p.A. contributed ₹7,873.81 Lakhs (4.72%) to consolidated turnover in FY25.
The subsidiary's net worth of ₹8,512.36 Lakhs represents 9.73% of the group's total net worth.
Judicial liquidation was initiated by the Ordinary Court of Ravenna on March 17, 2026.
The process follows an appeal by the subsidiary's Board of Statutory Auditors regarding corporate insolvency.
Court-appointed liquidators (Curatori) have taken over management of the subsidiary's assets.

💡 Investors should prepare for potential asset impairment charges and a reduction in consolidated net worth. Monitor upcoming quarterly results for the specific financial impact and management's plan to replace the lost revenue stream.

Camlin Fine Sciences Postpones Vinpai Tender Offer to May 2026; No Squeeze-Out Planned

🔵 WATCH ⭐ 7/10

M&A 📅 17 Mar 2026, 12:20 AM

Camlin Fine Sciences (CFSL) has updated the timeline for its mandatory tender offer for Vinpai shares, shifting the filing deadline from February to early May 2026. The delay is attributed to Indian foreign exchange regulations and the need to incorporate Vinpai's 2025 annual financial results into the offer documentation. Notably, CFSL has decided not to proceed with a squeeze-out, choosing instead to keep Vinpai listed on Euronext Growth Paris to support future debt restructuring and development. The offer price for the remaining shares remains fixed at Euro 3.60 per share.

Tender offer filing for Vinpai shares postponed from February 2026 to early May 2026
CFSL currently holds 83.82% share capital and 80.86% voting rights in Vinpai
The purchase price for the remaining shares is maintained at Euro 3.60 per share
Company decided against a squeeze-out procedure to keep Vinpai listed on Euronext Growth Paris

💡 Investors should monitor the successful completion of the tender offer in May and the subsequent impact of Vinpai's 2025 financial results on CFSL's consolidated balance sheet. The decision to keep Vinpai listed suggests a strategy of maintaining financial flexibility for the subsidiary rather than full private control.

Camlin Fine Sciences Faces ₹47.08 Crore GST Demand and Penalty

🔴 NEGATIVE ⭐ 7/10

REGULATORY 📅 16 Mar 2026, 11:59 PM

Camlin Fine Sciences has received an order from the CGST & Central Excise department for a total demand of approximately ₹47.08 crore. This includes a demand for ineligible Input Tax Credit (ITC) of ₹23.54 crore and an equivalent penalty of ₹23.54 crore for the period FY 2019-20 to FY 2022-23. The dispute stems from ITC claims on trade payables that remained outstanding for more than 180 days. While the company plans to appeal the order, the significant demand could impact future cash flows if the appeal is unsuccessful.

Total tax demand and penalty amount to ₹47.08 crore plus applicable interest.
The order cites ineligible ITC on trade payables outstanding for over 180 days between FY20 and FY23.
Specific breakdown includes ₹23.54 crore in ITC reversal and a ₹23.54 crore penalty under Section 74.
The company is in the process of filing an appeal against the order with the relevant authorities.

💡 Investors should monitor the progress of the appeal as the total demand represents a significant liability relative to the company's size. Watch for any further disclosures regarding the resolution of this tax dispute or its impact on quarterly provisions.

Camlin Fine Sciences to Hold Group Investor Meeting on March 10, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Mar 2026, 03:30 PM

Camlin Fine Sciences Limited has scheduled a group meeting with institutional investors and analysts on March 10, 2026, in Mumbai. The meeting is set to commence at 02:00 PM IST and will involve discussions based on publicly available information. The company has explicitly stated that no unpublished price-sensitive information (UPSI) will be shared during the interaction. This is a standard investor relations activity aimed at engaging with the financial community.

Group meeting with investors and analysts scheduled for March 10, 2026, in Mumbai.
Interaction is set to begin at 02:00 PM IST onwards.
Discussions will be strictly limited to publicly available information to ensure regulatory compliance.
The meeting schedule is subject to change due to unforeseen exigencies from either side.

💡 Investors should monitor for any post-event presentations or transcripts that may be uploaded to the stock exchanges for insights into management's outlook. No immediate action is required as this is a routine disclosure.

Camlin Fine Sciences Q3 FY26: Consolidated Net Loss Widens to ₹37.81 Crore

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 02 Mar 2026, 01:03 PM

Camlin Fine Sciences reported a consolidated revenue of ₹457.20 crore for Q3 FY26, showing a marginal sequential decline from ₹459.83 crore. The company's financial health remains under pressure as net losses widened significantly to ₹37.81 crore, compared to a loss of ₹14.94 crore in the previous quarter and a profit of ₹7.47 crore in the same period last year. High finance costs of ₹18.33 crore and depreciation charges of ₹16.73 crore continue to erode the bottom line. For the nine-month period ended December 2025, the company has accumulated a total consolidated net loss of ₹62.73 crore.

Consolidated Revenue from Operations stood at ₹457.20 crore, up 6% YoY but down 0.6% QoQ.
Net Loss for Q3 FY26 widened to ₹37.81 crore from a profit of ₹7.47 crore in Q3 FY25.
Finance costs remained elevated at ₹18.33 crore for the quarter, contributing to the net loss.
Nine-month consolidated revenue reached ₹1,350.58 crore with a total net loss of ₹62.73 crore.
Consolidated EPS for the quarter deteriorated to ₹(1.91) from ₹(0.77) in the preceding quarter.

💡 Investors should exercise caution as the company is struggling with persistent losses and high interest obligations. Monitor management's strategy for debt reduction and operational efficiency before considering new positions.

Camlin Fine Sciences Q3 Revenue at ₹572 Cr; EBITDA Margin Dips to 6.7% Amid Brazil Plant Fire

🔵 WATCH ⭐ 8/10

EARNINGS 📅 18 Feb 2026, 02:42 PM

Camlin Fine Sciences reported Q3 FY26 revenue of ₹572 crores, a 6% YoY increase, though EBITDA margins contracted to 6.7% due to pricing pressure in the Straights business. The company is strategically shifting towards high-margin Blends, which grew 11% YoY to ₹271 crores, aided by the Vinpai acquisition. Management expects Vanillin realizations to improve by $2-$3 per kg following a reduction in US tariffs from 50% to 25%. However, a massive fire at the Brazil unit has caused a total stock loss and temporary closure, necessitating the use of third-party tollers.

Revenue of ₹572 crores remained flat sequentially but grew 6% compared to the previous year's quarter.
Vanillin volume guidance for FY27 is 4,000 metric tons, with significant margin expansion expected from Q1 FY27.
Blends segment revenue reached ₹271 crores, including a ₹13 crore contribution from the newly acquired Vinpai.
Company initiated liquidation of loss-making subsidiaries in Europe and China to stop cash burn.
Exceptional items of ₹3.69 crores for acquisition costs and ₹2.25 crores for labor code provisions impacted PAT.

💡 Investors should watch for the insurance settlement regarding the Brazil fire and the actual margin uptick in the Vanillin segment next quarter. The consolidation of the Blends business and exit from loss-making geographies are key triggers for potential long-term profitability.

View All CAMLINFINE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 10.7% YoY in H1FY26 to INR 883.38 Cr. In Q2FY26, the Blends segment grew 78.4% YoY (from INR 44.5 Cr to INR 79.4 Cr), while Specialty Ingredients grew 9.1% YoY to INR 461.4 Cr. Aroma (Vanillin) volumes increased 40% QoQ, though net realization remained subdued due to global tariff situations.

Geographic Revenue Split

Q2FY26 revenue contribution: CFS India 53% (INR 244.0 Cr), CFS Mexico 26.1% (INR 120.1 Cr), CFS North America 15.1% (INR 69.4 Cr), CFS Brazil 8.7% (INR 40.0 Cr), CFS Vitafor 8.7% (INR 40.2 Cr), and CFS Europe 2.8% (INR 12.9 Cr).

Profitability Margins

Gross margins declined by approximately 200 bps YoY due to pricing pressure. PAT margin for Q2FY26 stood at -1.31% (Loss of INR 6.0 Cr) compared to 10.17% (Profit of INR 42.46 Cr) in Q2FY25, primarily impacted by lower realizations in the Straights business and costs associated with discontinued operations.

EBITDA Margin

Adjusted EBITDA margin for Q2FY26 was 7.27% (INR 33.41 Cr), a significant decline from 12.34% (INR 51.49 Cr) in Q2FY25. The margin compression is attributed to TBHQ and BHA prices falling from $8.5-$9.0 to $7.0, while fixed production costs remained stable.

Capital Expenditure

Capital Work-In-Progress (CWIP) stood at INR 14.65 Cr as of September 2025, up from INR 9.73 Cr in March 2025. The company is investing in the conversion of its Vanillin plant and technical upgrades to support the 4,000-ton production target for next year.

Credit Rating & Borrowing

Total borrowings as of September 2025 were INR 641.73 Cr (INR 290.07 Cr non-current and INR 351.66 Cr current). Finance costs for H1FY26 were INR 34.74 Cr, representing a 30% decrease from INR 49.59 Cr in H1FY25 due to debt management.

⚙️ Operational Drivers

Raw Materials

Key raw materials include precursors for TBHQ, BHA, and Vanillin. Raw material consumption accounted for 53.7% of total revenue in Q2FY26 (INR 246.72 Cr).

Import Sources

Not explicitly disclosed in available documents, though the company operates manufacturing hubs in India, Mexico, and Europe, suggesting localized sourcing in these regions.

Capacity Expansion

The Vanillin plant is currently running at 50% capacity utilization. The company plans to scale production to 100% to achieve a target of 4,000 tons in FY27, which is expected to reduce per-unit costs by $1.0-$1.5.

Raw Material Costs

Raw material costs as a percentage of revenue increased to 53.7% in Q2FY26 from 51.7% in Q2FY25. This 200 bps increase is driven by the inability to pass on costs as finished goods prices (TBHQ/BHA) dropped by 18-22%.

Manufacturing Efficiency

Vanillin manufacturing efficiency is currently hampered by 50% utilization. Moving to 100% utilization is projected to capture a $4.0 margin per kg on incremental sales, as all fixed costs are already absorbed at current levels.

Logistics & Distribution

Other expenses, including logistics and marketing, rose to INR 119.41 Cr in Q2FY26 (26% of revenue) from INR 102.07 Cr YoY, driven by the expansion of the Blends marketing team.

📈 Strategic Growth

Expected Growth Rate

18-20%

Growth Strategy

Growth will be driven by a 20% CAGR in the Blends business through an expanded global marketing team and the acquisition of Vinpai in France (78.68% stake). Additionally, Vanillin volumes are targeted to reach 4,000 tons next year as anti-dumping duties in Europe and de-stocking in the US conclude.

Products & Services

Antioxidants (TBHQ, BHA), Aroma chemicals (Vanillin, Ethyl Vanillin), and customized shelf-life extension Blends for food, pet food, and animal nutrition.

Brand Portfolio

CFS, Vitafor (acquired June 2024), and Vinpai (acquisition in progress).

New Products/Services

Integration of Vinpai's product portfolio is expected to contribute to the 20% growth target in the Blends vertical starting Q3FY26.

Market Expansion

Expansion into the French and broader European markets via the Vinpai acquisition and strengthening of the North American marketing team.

Strategic Alliances

Acquisition of 78.68% of Vinpai (France) for Euro 3.60 per share, with a simplified cash tender offer (OPAS) planned for the remaining 10-21% stake.

🌍 External Factors

Industry Trends

The industry is shifting toward customized antioxidant blends rather than straight ingredients. Camlin is positioning itself by acquiring Vitafor and Vinpai to move up the value chain into specialized food solutions.

Competitive Landscape

Facing heightened competition from local Indian manufacturers in the Straights business (TBHQ, BHA), leading to a price war that reduced realizations by ~$2 per kg.

Competitive Moat

Moat is built on vertical integration (producing precursors for Vanillin) and a global distribution network. However, this is currently challenged by low-cost local competitors in the TBHQ/BHA segments.

Macro Economic Sensitivity

High sensitivity to global inflation, particularly in the US, which has led to 'sluggishness' in the high-margin Blends business.

Consumer Behavior

Shift toward clean-label and sustainable food ingredients, driving the company's 20% growth focus on the Blends segment.

Geopolitical Risks

Anti-dumping duties in Europe on Vanillin have disrupted normal trade flows, though they are expected to benefit the company once local channel stocks are cleared by Q1FY27.

⚖️ Regulatory & Governance

Industry Regulations

Subject to French Stock Market Authority (AMF) regulations for the Vinpai acquisition and SEBI LODR for Indian operations. European anti-dumping duties on Vanillin are a key regulatory driver of current pricing strategy.

Environmental Compliance

The company tracks R&D and Capex specifically for environmental impact, as noted in the FY25 MDA report.

Taxation Policy Impact

Effective tax rate is volatile due to losses in discontinued operations; Q2FY26 saw a tax expense of INR 5.91 Cr despite a marginal PBT loss.

Legal Contingencies

Liquidation proceedings are underway for the China subsidiary. No specific values for pending court cases were disclosed in the provided transcripts.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the timeline for Vanillin price recovery; if realizations stay below $12/kg, the plant's return to 100% capacity may not yield the projected 20% margin improvement.